TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury
Fargol Mazaheri1, Nicolas Snaidero2,3, Gernot Kleinberger4,5
1German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany.
Abstract:
Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration. In the brain, TREM2 is predominantly expressed in microglia. Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques. We here investigate the consequences of TREM2 loss of function on the microglia transcriptome. Among the differentially expressed messenger RNAs in wild-type and Trem2-/- microglia, gene clusters are identified which represent gene functions in chemotaxis, migration and mobility. Functional analyses confirm that loss of TREM2 impairs appropriate microglial responses to injury and signals that normally evoke chemotaxis on multiple levels. In an ex vivo organotypic brain slice assay, absence of TREM2 reduces the distance migrated by microglia. Moreover, migration towards defined chemo-attractants is reduced upon ablation of TREM2 and can be rescued by TREM2 re-expression. In vivo, microglia lacking TREM2 migrate less towards injected apoptotic neurons, and outgrowth of microglial processes towards sites of laser-induced focal CNS damage in the somatosensory cortex is slowed. The apparent lack of chemotactic stimulation upon depletion of TREM2 is consistent with a stable expression profile of genes characterizing the homoeostatic signature of microglia.
Insights
Loss of the triggering receptor expressed on myeloid cells 2 (TREM2) impairs microglial cell migration and response to injury signals. This TREM2 deficiency affects neurodegenerative disease risk by altering key microglial functions.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Triggering receptor expressed on myeloid cells 2 (TREM2) is crucial for microglial function in the brain.
- TREM2 variants are associated with increased risk of neurodegenerative disorders, including Alzheimer's disease.
- Loss-of-function TREM2 variants impair microglial phagocytosis, lipid sensing, and amyloid plaque shielding.
Purpose of the Study:
- To investigate the impact of TREM2 loss of function on the microglia transcriptome.
- To analyze how TREM2 deficiency affects microglial migration and chemotaxis.
Main Methods:
- Comparative transcriptome analysis of wild-type and Trem2 knockout microglia.
- Functional assays including ex vivo organotypic brain slice assays and in vivo studies.
- Assessment of microglial migration towards chemoattractants and sites of CNS injury.
Main Results:
- TREM2 deficiency alters gene expression related to chemotaxis, migration, and mobility in microglia.
- Absence of TREM2 significantly impairs microglial migration in response to injury and chemoattractants.
- Microglial process outgrowth towards CNS damage is reduced in Trem2 knockout models.
- TREM2 re-expression can rescue the impaired migration phenotype.
Conclusions:
- Loss of TREM2 function compromises essential microglial migratory and chemotactic responses.
- Impaired microglial migration due to TREM2 deficiency may contribute to the pathogenesis of neurodegenerative diseases.
- TREM2 plays a vital role in orchestrating microglial behavior in response to brain injury and disease pathology.


